Indication

Methemoglobinemia

Methemoglobinemia is a hematologic disorder characterized by an abnormal accumulation of methemoglobin in circulating erythrocytes, leading to impaired systemic oxygen delivery and functional anemia. Read more about Methemoglobinemia

11 drugs 10 manufacturers

Advertisement

Drugs that treat it

Common Methemoglobinemia therapies.

Showing 1–9 of 11 drugs

METHYLENE BLUE

METHYLENE BLUE·METHEMOGLOBINEMIA
Hikma Pharmaceuticals USA
Filter & compare in the drug finder →Opens the drug finder with Methemoglobinemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Methemoglobinemia.

Methemoglobinemia is a hematologic disorder characterized by an abnormal accumulation of methemoglobin in circulating erythrocytes, leading to impaired systemic oxygen delivery and functional anemia.

Pathophysiologically, the condition occurs when heme iron is oxidized from its functional ferrous state to the ferric state, which prevents affected subunits from binding oxygen and shifts the oxygen dissociation curve of remaining normal hemoglobin to the left.

It can be congenital due to enzymatic deficiencies or hemoglobin mutations, but it most frequently arises as an acquired condition secondary to exposure to oxidizing drugs or toxins, with infants exhibiting heightened vulnerability.

Characteristic clinical manifestations include central cyanosis that is refractory to supplemental oxygen, chocolate-brown discoloration of arterial blood, fatigue, and tissue hypoxia that can progress to cardiac arrhythmias, seizures, or death at severe levels.

Personalize your experience

Follow Methemoglobinemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it